Outcome of the Board Meeting held on May 05, 2026
EMCURE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Emcure Pharmaceuticals reported strong FY2026 results with consolidated revenue of Rs 92,035 million, up 17% from Rs 78,960 million in FY2025. Net profit after tax grew 33% to Rs 9,413 million from Rs 7,075 million. Standalone revenue rose to Rs 52,432 million from Rs 43,819 million, with standalone net profit more than doubling to Rs 7,330 million from Rs 3,171 million. The Board recommended a final dividend of Rs 3.60 per share (36% payout). Key leadership appointments were approved: Dr Mukund Gurjar as Whole-time Director for 1 year and Mr Satish Mehta as Managing Director for 5 years. Exceptional items included Canada Drug Pricing legal settlements and New Labour Codes impact. The company completed acquisitions of Mantra Pharma Inc. and Cutimed Inc. in Canada, and made Zuventus Healthcare a wholly-owned subsidiary. Auditors B S R & Co. LLP issued an unmodified (clean) opinion.
Strong financial performance with double-digit revenue growth and near-doubling of standalone profit should be positive for the stock. Dividend payout and leadership continuity provide stability. Acquisitions expand the international footprint.